C12N 2800/24
Vectors characterised by the absence of particular element
Official title: Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
C12N2800/24 (Vectors characterised by the absence of particular element) appears on 98 US grants and 170 published applications in this corpus.
Search patents in C12N- Granted patents
- 98
- Published applications
- 170
- Assignees
- 104
- Inventors
- 273
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 6 |
| 2011 | 1 | 5 |
| 2012 | 2 | 4 |
| 2013 | 3 | 11 |
| 2014 | 1 | 10 |
| 2015 | 6 | 14 |
| 2016 | 8 | 11 |
| 2017 | 9 | 10 |
| 2018 | 5 | 14 |
| 2019 | 7 | 15 |
| 2020 | 9 | 13 |
| 2021 | 4 | 11 |
| 2022 | 12 | 17 |
| 2023 | 10 | 7 |
| 2024 | 8 | 13 |
| 2025 | 6 | 3 |
| 2026 | 4 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- VHH-containing heavy chain antibody and production thereof7 Jul 2026US 12,673,984 B2Universitätsklinikum Hamburg-Eppendorf
- Helper-dependent adenoviral gene therapy delivery and expression system16 Jun 2026US 12,655,448 B2Baylor College of Medicine
- Selection marker free methods for modifying the genome of bacillus and compositions thereof28 Apr 2026US 12,612,649 B2Danisco US Inc.
- Viral and non-viral nanoplasmid vectors with improved production14 Apr 2026US 12,600,984 B2Aldevron, LLC
- Antigen-binding molecules comprising unpaired variable domains18 Nov 2025US 12,473,378 B2Kymab Limited
- Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof6 Aug 2026US 2026/0226462 A1Elixirgen Therapeutics, Inc.
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Process for the manipulation of nucleic acids15 Jan 2026US 2026/0015630 A1Glaxosmithkline Biologicals SA
- Adenoviral Vectors Comprising Partial Deletions of E320 Nov 2025US 2025/0354172 A1The Wistar Institute
- Gene therapy DNA vector based on gene therapy DNA vector GDTT1.8NAS12 carrying HFE therapeutic gene for enhanced expression of the therapeutic gene, method of its production and use, Escherichia coli strain JM110-NAS/GDTT1.8NAS12-HFE carrying the gene therapy DNA vector, method of its production, method of the gene therapy DNA vector production on an industrial scale19 Jun 2025US 2025/0195690 A1Genetic Diagnostics and Therapy 21 Ltd
Most cited
By later US patents
- Integration-free human induced pluripotent stem cells from blood73US 8,048,675 B1iPierian, Inc. · 2011
- Immunization by inoculation of DNA transcription unit50US 5,643,578 ASt. Jude Children?S Research Hospital · 1997
- Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery46US 9,598,703 B2Association Institut De Myologie; Université Pierre Et Marie Curie (Paris 6); Centre National De La Recherche Scientifique; Institut National De La Santé De Lad Recherche MéDicale · 2017
- Methods for the production of iPS cells using non-viral approach45US 8,546,140 B2Cellular Dynamics International, Inc. · 2013
- Minicircle DNA vector preparations and methods of making and using the same37US 9,233,174 B2The Board of Trustees of the Leland Stanford Junior University · 2016